Recce Pharmaceuticals Ltd
ASX:RCE

Watchlist Manager
Recce Pharmaceuticals Ltd Logo
Recce Pharmaceuticals Ltd
ASX:RCE
Watchlist
Price: 0.36 AUD 7.46% Market Closed
Market Cap: 103.8m AUD

Operating Margin
Recce Pharmaceuticals Ltd

-168.9%
Current
-344%
Average
6.6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-168.9%
=
Operating Profit
-16.6m
/
Revenue
9.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
Recce Pharmaceuticals Ltd
ASX:RCE
103.8m AUD
-169%
US
Eli Lilly and Co
NYSE:LLY
735.9B USD
40%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
404B USD
26%
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK
45%
CH
Roche Holding AG
SIX:ROG
202.1B CHF
33%
CH
Novartis AG
SIX:NOVN
178.4B CHF
33%
UK
AstraZeneca PLC
LSE:AZN
160.5B GBP
24%
US
Merck & Co Inc
NYSE:MRK
205.3B USD
34%
IE
Endo International PLC
LSE:0Y5F
183.8B USD
11%
US
Pfizer Inc
NYSE:PFE
142.9B USD
27%

Recce Pharmaceuticals Ltd
Glance View

Market Cap
103.8m AUD
Industry
Pharmaceuticals

Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-01-15. The firm is engaged in development and commercialization of synthetic anti-Infectives designed to address antibiotic resistant superbugs and emerging viral pathogens. The firm pipeline consist of RECCE 327, RECCE 435, and RECCE 529 for viral infections with action against hyper-mutation on bacteria and viruses. Its patent candidate RECCE 327 is an intravenous therapy, which is developed for treatment of serious and potentially life-threatening infections including sepsis due to Gram-positive and Gram-negative bacteria, including their superbug forms. Its RECCE 435 is a broad-spectrum synthetic polymer antibiotic formulated for oral use. Its RECCE 529 is a synthetic polymer anti-infective, which is focused on viral indications. The Company’s RECCE technologies are targeting synergistic unmet medical needs.

RCE Intrinsic Value
0.05 AUD
Overvaluation 87%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-168.9%
=
Operating Profit
-16.6m
/
Revenue
9.8m
What is the Operating Margin of Recce Pharmaceuticals Ltd?

Based on Recce Pharmaceuticals Ltd's most recent financial statements, the company has Operating Margin of -168.9%.

Back to Top